ASH 2025: New Btk modalities advance in B cell malignancies

Btk-targeting therapies were a focus at the 2025 ASH meeting, underscoring the strong early-line performance of non-covalent inhibitors. A newer modality, Btk degraders, is being positioned as a solution for patients who have developed resistance to either covalent or non-covalent inhibitors. 

While BTK programs dominated much of the clinical discussion, the American Society for Hematology (ASH) 2025 meeting also delivered important readouts in other targets and disease areas (see last section of this article)...